DTC

Five things for pharma marketers to know: Wednesday, September 14, 2016

Five things for pharma marketers to know: Wednesday, September 14, 2016

By

Patients who ask for a prescription after seeing an ad are more likely to get one; Mylan's executive pay is now under scrutiny

Five things for pharma marketers to know: Monday, September 12, 2016

Five things for pharma marketers to know: Monday, September 12, 2016

By

Some drugmakers employ unsettling ads; Teva said the FDA may grant quick review for generic EpiPen; Sanofi and Google's Verily partner in diabetes

MM&M's top 5 stories in August 2016

MM&M's top 5 stories in August 2016

By

Shire hires Jennifer Aniston for a disease awareness campaign; critics argue that the direct-to-consumer ads for Opdivo are misleading, while Merck's Keytruda takes the lead in first-line cancer

DTC ads for Opdivo face further backlash

DTC ads for Opdivo face further backlash

By

Critics say the direct-to-consumer ad for the immuno-oncology therapy is misleading.

Five things for pharma marketers to know: Wednesday, August 10, 2016

Five things for pharma marketers to know: Wednesday, August 10, 2016

By

A new bill exempting CME reporting gains physician support; NYT op-ed calls Opdivo DTC ad "misleading;" Valeant to sell non-core assets worth $8 billion

Five things for pharma marketers to know: Tuesday, June 14, 2016

Five things for pharma marketers to know: Tuesday, June 14, 2016

By

Physicians debate DTC tax write-off; Novo Nordisk's Victoza shows 13% benefit in reducing cardiovascular risks; Shire to acquire Pfizer bowel drug

Industry criticizes FDA's proposed DTC studies

Industry criticizes FDA's proposed DTC studies

By

Pharma companies took issue with the methodology for the FDA's proposed studies of advertising tactics.

Five things for pharma marketers to know: Monday, May 16, 2016

Five things for pharma marketers to know: Monday, May 16, 2016

By

Pfizer buys Anacor; Harvard Medical School loosens rules for faculty ties to pharma; Vermont poised to pass price transparency bill

Lobbyists argue DTC ad tax deduction may be a casualty of reform

Lobbyists argue DTC ad tax deduction may be a casualty of reform

By

Advertising lobbyist said eliminating the DTC ad tax deduction is a real threat to the industry.

Novartis launches DTC campaign for Entresto

Novartis launches DTC campaign for Entresto

By

The loss of patent exclusivity for cancer drug Gleevec contributed to a 12% sales drop, but the drugmaker expects sales from Entresto and Cosentyx to pick up the slack.

When it comes to professional ads, print makes its comeback

When it comes to professional ads, print makes its comeback

By

Following print's best year since 2011, it's time to rewrite those journal-advertising obituaries. Medical-surgical print journal spending in 2015 was up 8.4% to $372 million.

Drugmakers go to DTC to promote IBS drugs

Drugmakers go to DTC to promote IBS drugs

By

The launch this week of the first DTC campaign for Viberzi follows a wave of direct-to-consumer campaigns focused on promoting treatments for the two types of IBS.

MannKind reworks commercial strategy for Afrezza

MannKind reworks commercial strategy for Afrezza

By

After buying back the rights to the therapy, the biopharmaceutical company is building a endocrinology sales force and hiring a new advertising agency.

Larry Dobrow on the Worst DTC ads of 2015

Larry Dobrow on the Worst DTC ads of 2015

By

One side effect (pun super-deliberately intended) of prompting pharma creatives to come up with new go-to visuals is that, well, not every idea or execution is a keeper.

A ranking of 2015's DTC Ads

A ranking of 2015's DTC Ads

Great DTC pharma advertising during the last year or so has been "sparse," says SSCG Media Group president Debbie Renner. Still, here are her top 10 picks for 2015.

2015 DTC spending: All the data in one place

2015 DTC spending: All the data in one place

Drugmakers spent 20% more on DTC ads in 2015 than in 2014. Eli Lilly was the top spender, shelling out $220.4 million to promote Cialis, its erectile dysfunction drug.

DTC Report 2016: Gut Check

DTC Report 2016: Gut Check

By

DTC is facing a new test from physicians and politicians. Here's why critics fear a deluge, and how they're pushing back.

Another physician group raises concerns about DTC

Another physician group raises concerns about DTC

By

The American College of Physicians questioned the role direct-to-consumer advertising plays in contributing to prescription drug costs.

Five things for pharma marketers to know: Monday, March 28, 2016

Five things for pharma marketers to know: Monday, March 28, 2016

By

Experts say DTC spending is a waste; Alder BioPharma's migraine drug meets study goal; sources tell Stat that execs are leaving Verily Life Sciences

The FDA wants to study DTC tactics

The FDA wants to study DTC tactics

By

The agency has proposed two studies to investigate the use of superimposed text and the use of animated characters.

Omnicom formalizes health group led by CDM's Wise

Omnicom formalizes health group led by CDM's Wise

By

The division, dubbed Omnicom Health Group, claims to serve 70% of the top 100 pharma brands.

Five things for pharma marketers to know: Thursday, February 18, 2016

Five things for pharma marketers to know: Thursday, February 18, 2016

By

Lawmaker seeks to stop DTC ads for newly approved drugs; testosterone therapy helps sexual function; the FDA requests more data about Catalyst's rare drug

Celebrity pharma ads: Opportunity or PR disaster?

Celebrity pharma ads: Opportunity or PR disaster?

By

Tapping celebrities for brand or awareness campaigns ensures a high degree of attention, but such arrangements come with concerns that "regular" ones do not.

The best and worst pharma celebrity moments

The best and worst pharma celebrity moments

By

We present to you our picks for the best and worst moments in celebrity healthcare spokespersonship—plus a few more that, frankly, we can't find anywhere.

Is This the End of Agency Diversification?

Is This the End of Agency Diversification?

By

DTC and OTC/wellness can borrow from mainstream consumer shops. Professional marketing may pose a tougher sell.

BMS CEO defends use of DTC to promote cancer drug

BMS CEO defends use of DTC to promote cancer drug

By

The drugmaker's CEO said the campaign helps dispel pessimism created from a history of cancer drugs that lack "significant value."

What the AMA's Proposed DTC Ban Overlooks

What the AMA's Proposed DTC Ban Overlooks

While DTC advertising does significantly impact consumer demand, most evidence suggests the majority of this demand benefits the overall state of consumer health.

Characters in DTC Ads Used with Little Reason

Characters in DTC Ads Used with Little Reason

Many of the characters we are now meeting do not appear to be directed at a patient insight or purposefully used to de-stigmatize a disease.

Five things for pharma marketers to know: Wednesday, January 6, 2016

Five things for pharma marketers to know: Wednesday, January 6, 2016

By

Lilly's Jardiance starting to gain market share; Merck "raring" to make acquisitions; Sanofi said it will stop marketing Afrezza

Sanofi to stop marketing Afrezza, citing low Rx

Sanofi to stop marketing Afrezza, citing low Rx

By

Sanofi spent $3.75 million on advertising for Afrezza in the third quarter of 2015 yet the therapy only brought in about $2 million in revenue.

OPINION

Email Newsletters